Hi,
My mother was diagnosed with AML in early 2004 and she relapsed within weeks. Her counts remained quite low after her second induction treatment due to secondary MDS. She participated in the Phase 2 PR1 Peptide trial for AML last year and her counts have been improving. Early 2005 her WBC was around 1.9 and platelets were 18 and the last few months her wbc has been around 3.3 and platelets have been in 50’s and 60’s. She participated in the trial with the hope of preventing a relapse. My mother didn’t have any side effects from the vaccine. I try to keep up with the vaccine trials for AML and MDS. I just found this one today.
http://clinicaltrials.gov/ct/show/NCT00433745?order=10
This information was posted by a member on the LLS board –
Trial of pr1 ( promising based on Phase 2 results) in combination with Wilms tumor vaccine (wt1)is being conducted at the NIH for patients in remission who are HLA-A2 with cml aml and mds.It is expected to progress quickly to Phase 2 ( safety of each agent has been demonstrated)
In addition wt1 alone is available to above with active disease in a different trial.Contact info,Dr Katy Rezvani 1-301-435-4107 rezvanik@nhlbi.nih.gov
Here is a phase I pilot with WT1 vaccine at Sloan Kettering Cancer Center in NY.
http://clinicaltrials.gov/show/NCT00398138
I hope these clinical trials can help someone.. Pat
.
